STAT

AUGUST 22, 2024

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and potentially harms — the billions of people of color on the planet.

Drug Development 321

Drug Development 321

STAT

OCTOBER 29, 2024

based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based

Drug Development 352

Drug Development 352

STAT

OCTOBER 9, 2024

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs.

Drug Development 337

Drug Development 337

STAT

SEPTEMBER 3, 2024

Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive at the drug company G.D. The group has raised more than $600 million for research, launched nearly 100 clinical trials, and helped bring more than 15 new drugs to market. She was told she had three years to live.

Drug Development 362

Drug Development 362

PharmaVoice

OCTOBER 15, 2024

A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.

Drug Development 289

Drug Development 289

STAT

MAY 20, 2024

But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing. Artificial intelligence is a rapidly improving technology. To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets.

Drug Development 360

Drug Development 360

STAT

APRIL 22, 2024

And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation. In its absence, the house of cards comes down. For my 6-year-old son, Charlie, dystrophin will govern how long he lives. Read the rest…

Drug Development 321

Drug Development 321

STAT

SEPTEMBER 9, 2024

To be clear, I’m not writing this to claim credit for discovery or development of GLP-1s or anything like that. Rather, I think the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. Read the rest…

Drug Development 356

Drug Development Pharmaceutical Companies Pharmaceutical Companies 356

STAT

MARCH 14, 2024

Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

Drug Development 320

Drug Development 320

STAT

AUGUST 19, 2024

And the startup was based in Salt Lake City, Utah — an area better known for its ski slopes and connection to the Church of Jesus Christ of Latter-day Saints than drug development.      Continue to STAT+ to read the full story…

Medical Schools 362

Medical Schools Drug Development Pharmaceutical Companies Pharmaceutical Companies 362

STAT

SEPTEMBER 5, 2024

Pediatric cancer researchers hoping to advance care have had to rely largely on repurposing newer drugs developed for adults — a limited strategy, as pediatric malignancies often have unique biology that require unique drugs.    On Thursday, though, two U.K.

Chemotherapy 324

Chemotherapy Drug Development 324

STAT

JANUARY 30, 2024

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

Drug Development 334

Drug Development 334

STAT

JANUARY 17, 2024

Recursion, a biotechnology firm that uses machine learning for drug development and and which was announcing that it is rolling out AI-driven drug discovery software with tech giant Nvidia, decided to seize the moment. It was going to rain.

Drug Development 347

Drug Development 347

STAT

JULY 12, 2024

Over the past decade, precision medicine has evolved from merely creating personalized treatment plans and delivery methods to being integral throughout the entire drug development process. A similar approach needs to be implemented at scale for clinical trials. Read the rest…

Drug Development 302

Drug Development 302

STAT

SEPTEMBER 5, 2024

We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

Drug Development 326

Drug Development 326

STAT

SEPTEMBER 3, 2024

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer. 

Drug Development 347

Drug Development 347

STAT

AUGUST 8, 2024

” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1.

Drug Pricing 278

Drug Pricing Drug Development 278

STAT

OCTOBER 17, 2024

Likely more than in any other industry, patents are essential to incentivize R&D in biopharmaceuticals due to the extremely lengthy, costly, and risky nature of drug development.

Drug Development 339

Drug Development Pharmaceutical Companies Pharmaceutical Companies 339

STAT

MAY 22, 2024

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function.

Immunization 334

Immunization Immunity Drug Development 334

STAT

AUGUST 20, 2024

19 letter that the House China committee sent to the Food and Drug Administration.    The bipartisan inquiry jeopardizes yet another aspect of drug development for which drugmakers increasingly rely on China, where it’s cheaper.   “For over a decade, it appears that U.S.

Hospitals 350

Hospitals Drug Development 350

STAT

AUGUST 22, 2024

And will Recursion Pharma, the AI drug developer, live up to all the hype? What does the hiring of a well-known industry dealmaker mean for the future of BioMarin Pharmaceuticals? Can Eli Lilly’s blockbuster obesity medicine lower the risk of diabetes? ” Read the rest…

Diabetes 281

Diabetes Drug Development 281

STAT

OCTOBER 25, 2023

The drug, called BIIB080, is being developed by Biogen. “We are very encouraged by the consistency of the data,” said Priya Singhal, Biogen’s chief of drug development, while also emphasizing the company is not trying to oversell the significance of the findings.

Drug Development 361

Drug Development 361

STAT

JUNE 27, 2024

STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.   Read the rest…

Drug Development 312

Drug Development 312

STAT

OCTOBER 14, 2024

Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has seen an even more significant amount of activity: autoimmune diseases.

Immunization 363

Immunization Immunity Drug Development 363

STAT

SEPTEMBER 20, 2024

The Food and Drug Administration on Friday approved the first treatment for Niemann-Pick disease, type C, the culmination of years of advocacy and stutter-start drug development efforts in the rare neurological condition.

Drug Development 262

Drug Development 262

STAT

JULY 25, 2024

Many people were stunned when an FDA advisory committee voted “no” on a new drug application for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) earlier this summer. Several things were stacked against approval: The FDA greenlights only about 50 new drugs each year. I was not among them.

Compounding 341

Compounding Drug Development 341

STAT

MAY 9, 2024

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S.

Drug Development 297

Drug Development 297

STAT

OCTOBER 30, 2024

Axonis will use the funds to jump into an emerging area of drug development: non-addictive therapies for pain.  Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and others also participated in the financing round.   Continue to STAT+ to read the full story…

Drug Development 286

Drug Development 286

STAT

APRIL 18, 2024

After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development.

Drug Development 326

Drug Development 326

STAT

SEPTEMBER 4, 2024

This type of treatment has become a hot spot in drug development, leading to several acquisitions over the last year.    Novartis is the leading producer of radiopharmaceutical or radioligand therapies, an emerging type of cancer treatment in which a potent dose of radioactive molecules is dispatched to harm cancer cells.

Drug Development 302

Drug Development 302

STAT

JULY 25, 2024

The reorganization comes at a time when industry — from medical device makers to drug developers to health IT vendors — are itching to influence developing technology regulation, in particular for AI.

Drug Development 341

Drug Development 341

STAT

SEPTEMBER 12, 2024

patient information is a national security concern, as is the overreliance on China for drug development. BIOSECURE proponents argue that allowing the Chinese Communist Party access to U.S. They aren’t wrong. Protecting that information and being able to make our own medicines should be a national priority.

Pharmaceutical Companies 341

Pharmaceutical Companies Pharmaceutical Companies Drug Development 341

STAT

MAY 23, 2024

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

Drug Development 302

Drug Development 302

STAT

AUGUST 14, 2024

It’s also the latest attempt to deal with one of the biggest challenges in drug development: What should a company do when it wins big? But inventing a mega-blockbuster — in this case novel drugs that treat obesity and diabetes — brings its own set of issues. It’s a sizeable and conspicuous bet.

Diabetes 360

Diabetes Drug Development 360

STAT

DECEMBER 21, 2023

Poor clinical trial diversity creates gaps in the understanding of diseases and the drugs that treat them. The knowledge gaps make it difficult for doctors and patients to make the right decisions about their health care, and they undermine drug development, according to the National Institutes of Health.

Drug Development 347

Drug Development 347

STAT

DECEMBER 10, 2024

Fox Foundation’s annual meeting in New York — came from an unlikely source: Koneksa Health, which helps drug developers use smartphone apps and wearables to study whether their treatments work. But amid all the jostling to find the next use case for GLP-1s, the proposition in October — the day before the Michael J.

Diabetes 319

Diabetes Drug Development 319

STAT

JUNE 17, 2024

The vote means the board will decide in a follow-up meeting whether to pursue an upper payment limit for the drug, which an affordability review found cost an average of roughly $47,000 per patient in 2022. Some drug makers are halting or reshaping research into rare disease drugs over concerns they may not recoup their costs.

Drug Development 291

Drug Development 291